Cathepsin B levels in urine from bladder cancer patients

Oncology Reports

Volumn 7, Issue 6, 2000, Pages 1395-1399

  Eiján, Ana María ^a   Sandes, Eduardo ^a   Puricelli, Lydia ^a   De Kier Joffé, Elisa Bal ^a   Casabé, Alberto Ricardo ^a  

^a Instituto de Oncologia Angel H Roffo   (Argentina)

Author keywords

Bladder cancer; Cathepsin B; Lysosomal endopeptidase; Urine tumor marker

Indexed keywords

CATHEPSIN B; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLADDER TUMOR; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOBLOTTING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; URINE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CATHEPSIN B; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0034320121     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.6.1395     Document Type: Article

References (29)

1. Catalona W: Urothelial tumors of the urinary tract. In: Cambell's Urology. Walsh P, Retk A, Stamey J, et al (eds). Vol. 6. Saunders, Philadelphia, PA, pp 1094-1158, 1992.
2. Nguyen M, Watanabe H, Budson AI, Richie JP and Folkman J: Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 85: 241-242, 1993.
3. Mostofi FK, Sobin LH and Toloni H (eds): Histological typing of urinary bladder tumors. In: International Histological Classification of Tumors. Vol. 10. World Health Organization, Geneva, 1973.
4. Koss LG: Tumors of the urinary bladder. In: Atlas of Tumor Pathology. Fascicle 11, 2nd series. Armed Forces Institute of Pathology, Washington, DC, 1975.
5. Sloane BF, Moin K and Lah TT: Regulation of lysosomal endopeptidases in malignant neoplasia. Biochem Mol Aspects Select Cancers 2: 411-466, 1994.
6. Nadji M, Fresno M, Nassiri M, Conner Gm Herrero A and Morales AR: Cathepsin D in host stromal cells, but not in tumor cells, is associated with aggressive behavior in node negative-breast cancer. Hum Pathol 27: 890-895, 1996.
7. Nort JS and Buttle DJ: Molecules in focus. Cathepsin B. Int J Biochem Cell Biol 29: 715-720, 1997.
8. Turk B, Turk V and Turk D: Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol Chem 378: 141-150, 1997.
9. Weiss RE, Liu BC-S, Shlerin T, Dubeau L and Droller MJ: Mechanisms of human bladder tumor invasion: role of protease cathepsin. J Urol 144: 798-804, 1990.
10. Yan S, Sameni M and Sloane BF: Cathepsin B and human tumor progression. Biol Chem 379: 113-123, 1998.
11. Frosch BA, Berquin I, Emmert-Buck MR, Moin K and Sloane BF: Molecular regulation, membrane association and secretion of tumor cathepsin B. APMIS 107: 28-37, 1999.
12. Iacobuzio-Donahue CA, Shuja S, Cai J, Peng P and Murnane MJ: Elevations in cathepsin B protein content and enzyme activity occur independently of glycosy lation during colorectal tumor progression. J Biol Chem 272: 29190-29199, 1997.
13. Hirai K, Yokoyama M, Asano G and Tanaka S: Expression of cathepain B and cystatin C in human colorectal cancer. Hum Pathol 30: 680-686, 1999.
14. Maguire TM, Shering SG, Duggan CM, McDermott EW, O'Higgins NJ and Duffy MJ: High levels of cathepain B predict poor outcome in patients with breast cancer. Int J Biol Markers 13: 139-144, 1998.
15. Foekens JA, Kos J, Peters HA, Krasovec M, Look MP, Cimerman N, van Mijer-Gelder ME, Henzen-Logmans SC, van Putten WL and Klijn JG: Prognostic significance of cathepsins B and L in primary human breast cancer. K Clin Oncol 16: 1013-1021, 1998.
16. Sinha AA, Quast BJ, Wilson MJ, Reddy PK, Gleason DF and Sloane BF: Codistribution of procathepsin B and cathepsin B forms in human prostate tumors detected by confocal and immunofluorescence microscopy. Anat Rec 252: 281-289, 1998.
17. Mori M, Kohli A, Baker SP, Savas L and Fraire AE: Laminin and cathepsin B as prognostic factors in stage I non-small cell lung cancer: are they useful? Mod Pathol 10: 572-577, 1997.
18. Visscher DW, Sloane BF, Sameni M, Babiarz JW, Jacobson J and Crissman JD: Clinicopathologic significance of cathepsin B immunostining in transitional neoplasia. Mod Pathol 7: 76-81, 1994.
19. Eiján AM, Casabé AR, Puricelli L, Pasik L, Malagrino H, Matos E and Bal de Kier Joffé E: Levels of plasma cysteine-proteinase activity in bladder cancer patients. Oncol Rep 4: 447-450, 1997.
20. Sobin LH and Wittekind CH (eds): UICC TNM Classification of malignant tumors. 5th edition. New York, Inc., 1997.
21. World Health Organization. International Histological classification of tumors. World Health Organization, 1969-1981. 2nd edition. Springer-Verlag, Berlin, 1988.
22. Abou-Farhah KM, Menheere PP, Nieman FH, Jankneg RA and Arends JW: Urine laminin PI assessment discriminates between invasive and non-invasive urothelial cell carcinoma of the bladder. Ural Int 51: 204-208, 1993.
23. Malmstrom PU, Larsson S and Johansson S: Urinary fibronectin in diagnosis and follow-up of patients with urinary bladder cancer. Brit J Urol 72: 303-310, 1993.
24. Puricelli L, De Lorenzo M, Eiján AM, Malagrino H, Kes S, Pasik L, Matos E and Bal de Kier Joffé E: Increased levels of urinary basic fibroblast growth factor in bladder cancer patients. Oncol Rep 4: 619-622, 1997.
25. Schamhart DHJ, de Reijke TM, van der Poel HG, Witjes JA, de Boer EC, Jurth K-H and Schalken JA: The Bard BTA test: its mode of action, sensitivity, specificity, compared to cytology of voided urine, in the diagnosis of superficial bladder cancer. Eur Urol 34: 99-106, 1998.
26. Ellis WJ, Blumenstein BA, Ishak LM, Enfield DL and the Multicenter Study Group: Clinical evaluation of the BTA Trak assay and comparison to voided urine cytology and BTA test in patients with recurrent bladder tumors. Urology 50: 882-887, 1997.
27. Soloway MS, Briggman JV, Crpinito GA, Chodak GW, Church PA, Lamm DL, et al: Use of a new tumor marker, urinary NMP-22, in the detection of transitional cell carcinoma of the bladder. J Urol 156: 363-367, 1996.
28. Stampfer DS, Carpinito GA, Rofriguez-Villanueva J, Willsey LW, Dinney CP, Grossman HB, et al: Evaluation of NMP-22, in the detection of transitional cell carcinoma of the bladder. J Urol 159: 394-398, 1998.
29. Landman J, Chang Y, Kavaler E, Doller MJ and Liu BC-S: Sensitivity and specificity of NMP-22, telomerase and BTA in the detection of human blader cancer. Urology 52: 398-402, 1998.